<DOC>
	<DOCNO>NCT00002759</DOCNO>
	<brief_summary>Phase I trial study effectiveness irinotecan plus cyclosporine phenobarbital treating patient solid tumor lymphoma refractory standard therapy . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Cyclosporine phenobarbital may enhance effectiveness irinotecan .</brief_summary>
	<brief_title>Irinotecan Plus Cyclosporine Phenobarbital Treating Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose irinotecan ( CPT-11 ) infuse weekly cyclosporine ( CYSP ) patient solid tumor lymphoma refractory standard therapy . II . Determine whether CYSP modulate pharmacokinetics pharmacodynamics CPT-11 active metabolite , SN-38 . III . Determine whether phenobarbital modulates pharmacokinetics pharmacodynamics CPT-11 SN-38 . OUTLINE : This dose escalation study irinotecan . Patients stratify accord gender . Part I : Patients receive cyclosporine IV 6 hour irinotecan IV 90 minute weekly 4 week . Courses repeat every 6 week absence unacceptable toxicity disease progression . Cohorts 3-12 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose least one third patient experience dose limit toxicity ( DLT ) . Part IIA : If DLT diarrhea part I , part IIA open . Patients receive oral phenobarbital , cyclosporine part I , irinotecan MTD part I . Dose escalation occurs part I determine new MTD . If DLT continue diarrhea , study close . Part IIB : If DLT neutropenia part I , part IIB open . Patients receive cyclosporine part I escalate dos irinotecan determine new MTD . Part III : If DLT neutropenia part IIA DLT part IIB , patient receive phenobarbital , cyclosporine , irinotecan MTD determine part IIA part IIB . Dose escalation continue new MTD determine .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Malignant solid tumor lymphoma refractory standard therapy therapy proven benefit exist No leukemia Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month WBC least 3,500/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Bilirubin great 1.5 mg/dL AST/ALT le twice normal ( unless due disease ) PT PTT normal Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min No history congestive heart failure require medical therapy No clinically significant life threaten cardiac arrhythmia No history significant pulmonary disease lymphangitic lung disease No hypersensitivity cyclosporine cremophore No history manifest latent porphyria hypersensitivity barbiturate ( part study use phenobarbital ) No history inflammatory bowel disease require therapy No chronic diarrhea syndrome paralytic ileus No medical psychiatric condition precludes inform consent Not pregnant Effective contraception require fertile woman PRIOR CONCURRENT THERAPY : At least 4 week since prior biologic therapy At least 2 week since prior colony stimulate factor At least 4 week since prior chemotherapy ( least 6 week since nitrosoureas mitomycin ) No prior bleomycin irinotecan At least 4 week since prior radiotherapy great 25 % bone marrow Minimum time interval prior therapy eligibility shorten 2 week phenobarbital administer Concurrent use medication affect central nervous cardiovascular system ( e.g. , anticonvulsant , calcium channel blocker , oral contraceptive ) must approve Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>neutropenia</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>